Acetylon Pharmaceuticals Obtains $100,000,000 New Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3c04c92e-546a-4f66-a02c-52243112dad8
Date
7/30/2013
Company Name
Acetylon Pharmaceuticals
Mailing Address
70 Fargo Street Boston, MA 02210
Company Description
Acetylon intends to pursue the clinical development and commercialization of next generation, selective, small-molecule Histone Deacetylase (HDAC) inhibitors with enhanced therapeutic effectiveness and tolerability versus current alternatives.
Website
http://www.acetylon.com
Transaction Type
Venture Equity
Transaction Amount
$100,000,000
Transaction Round
Undisclosed
Proceeds Purposes
Acetylon intends to use the money for the research and testing of ACY-1215, a potential myeloma-fighting cancer drug, as well as three other cancer treatments.
M&A Terms
Venture Investor
Celgene Corporation